IFG Advisory’s Genmab GMAB Stock Holding History

IFG Advisory’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.87K	Buy	+250	New	+$6.64K	﹤0.01%	1922

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IFG Advisory's GMAB Position: Q2 2026 in Review

IFG Advisory opened a new position in Genmab (GMAB) in Q2 2026: 250 shares worth $6.87K. The stake represents ﹤0.01% of the portfolio and ranks #1922 among its holdings.

289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

IFG Advisory held 250 shares of Genmab worth $6.87K as of Q2 2026.
Genmab was a new IFG Advisory position in Q2 2026.
Genmab made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #1922 holding.
289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.